Come up with a name for your new list and we'll add to it:
Exicure raised a round of funding on September 28, 2017. Investors include
Max-1 Acquisition Corporation.
Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) ar…